tetano
Editor, Senior Moderator
Sci Rep
. 2024 Jan 6;14(1):712.
doi: 10.1038/s41598-023-50450-4. Studying SARS-CoV-2 interactions using phage-displayed receptor binding domain as a model protein
Beatriz Pérez-Massón[SUP] 1 [/SUP], Yazmina Quintana-Pérez[SUP] 1 [/SUP], Yaima Tundidor[SUP] 1 [/SUP], Dayana Pérez-Martínez[SUP] 1 [/SUP], Camila Castro-Martínez[SUP] 1 [/SUP], Mario Pupo-Meriño[SUP] 2 [/SUP], Ivette Orosa[SUP] 1 [/SUP], Ernesto Relova-Hernández[SUP] 1 [/SUP], Rosmery Villegas[SUP] 2 [/SUP], Osmany Guirola[SUP] 3 [/SUP], Gertrudis Rojas[SUP] 4 [/SUP]
Affiliations
SARS-CoV-2 receptor binding domain (RBD) mediates viral entry into human cells through its interaction with angiotensin converting enzyme 2 (ACE2). Most neutralizing antibodies elicited by infection or vaccination target this domain. Such a functional relevance, together with large RBD sequence variability arising during viral spreading, point to the need of exploring the complex landscape of interactions between RBD-derived variants, ACE2 and antibodies. The current work was aimed at developing a simple platform to do so. Biologically active and antigenic Wuhan-Hu-1 RBD, as well as mutated RBD variants found in nature, were successfully displayed on filamentous phages. Mutational scanning confirmed the global plasticity of the receptor binding motif within RBD, highlighted residues playing a critical role in receptor binding, and identified mutations strengthening the interaction. The ability of vaccine-induced antibodies to inhibit ACE2 binding of many mutated RBD variants, albeit at different extents, was shown. Amino acid replacements which could compromise such inhibitory potential were underscored. The expansion of our approach could be the starting point for a large-scale phage-based exploration of diversity within RBD of SARS-CoV-2 and related coronaviruses, useful to understand structure-function relationships, to engineer RBD proteins, and to anticipate changes to watch during viral evolution.
. 2024 Jan 6;14(1):712.
doi: 10.1038/s41598-023-50450-4. Studying SARS-CoV-2 interactions using phage-displayed receptor binding domain as a model protein
Beatriz Pérez-Massón[SUP] 1 [/SUP], Yazmina Quintana-Pérez[SUP] 1 [/SUP], Yaima Tundidor[SUP] 1 [/SUP], Dayana Pérez-Martínez[SUP] 1 [/SUP], Camila Castro-Martínez[SUP] 1 [/SUP], Mario Pupo-Meriño[SUP] 2 [/SUP], Ivette Orosa[SUP] 1 [/SUP], Ernesto Relova-Hernández[SUP] 1 [/SUP], Rosmery Villegas[SUP] 2 [/SUP], Osmany Guirola[SUP] 3 [/SUP], Gertrudis Rojas[SUP] 4 [/SUP]
Affiliations
- PMID: 38184672
- PMCID: PMC10771503
- DOI: 10.1038/s41598-023-50450-4
SARS-CoV-2 receptor binding domain (RBD) mediates viral entry into human cells through its interaction with angiotensin converting enzyme 2 (ACE2). Most neutralizing antibodies elicited by infection or vaccination target this domain. Such a functional relevance, together with large RBD sequence variability arising during viral spreading, point to the need of exploring the complex landscape of interactions between RBD-derived variants, ACE2 and antibodies. The current work was aimed at developing a simple platform to do so. Biologically active and antigenic Wuhan-Hu-1 RBD, as well as mutated RBD variants found in nature, were successfully displayed on filamentous phages. Mutational scanning confirmed the global plasticity of the receptor binding motif within RBD, highlighted residues playing a critical role in receptor binding, and identified mutations strengthening the interaction. The ability of vaccine-induced antibodies to inhibit ACE2 binding of many mutated RBD variants, albeit at different extents, was shown. Amino acid replacements which could compromise such inhibitory potential were underscored. The expansion of our approach could be the starting point for a large-scale phage-based exploration of diversity within RBD of SARS-CoV-2 and related coronaviruses, useful to understand structure-function relationships, to engineer RBD proteins, and to anticipate changes to watch during viral evolution.